中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

45 records (took 0.023 seconds)

    Recombinant E-selectin made in insect cells
    21.
    发明申请
    Recombinant E-selectin made in insect cells 审中-公开
    在昆虫细胞中制备的重组E-选择素

    公开(公告)号：US20070244043A1

    公开(公告)日：2007-10-18

    申请号：US11369788

    申请日：2006-03-07

    Applicant: Gale Smith ,  Peter Pushko ,  Vittoria Cioce

    Inventor： Gale Smith ,  Peter Pushko ,  Vittoria Cioce

    IPC: A61K48/00 ,  C07H21/04 ,  C07K14/00 ,  C12N1/21 ,  C12N5/06 ,  C12N7/01 ,  C12P1/04

    CPC classification number: C07K14/70564 ,  A61K38/00

    Abstract: The inventive features include recombinant mammalian E-selectin peptides, nucleic acids encoding said peptides, vectors and cells having these nucleic acids, and methods of making the peptides. Further inventive features include methods of treating diseases and conditions associated with inflammation using recombinant mammalian E-selectin peptides to induce mucosal tolerance to E-selectin.

    Abstract translation: 本发明的特征包括重组哺乳动物E-选择蛋白肽，编码所述肽的核酸，具有这些核酸的载体和细胞，以及制备肽的方法。 其它发明特征包括使用重组哺乳动物E-选择蛋白肽治疗与炎症相关的疾病和病症以诱导对E-选择素的粘膜耐受的方法。

    Alphavirus RNA replicon systems
    24.
    发明授权
    Alphavirus RNA replicon systems 失效
    甲病毒RNA复制子系统

    公开(公告)号：US06531135B1

    公开(公告)日：2003-03-11

    申请号：US09598569

    申请日：2000-06-21

    Applicant: Robert E. Johnston ,  Nancy L. Davis ,  Jonathan F. Smith ,  Peter Pushko ,  Michael Parker ,  George Ludwig

    Inventor： Robert E. Johnston ,  Nancy L. Davis ,  Jonathan F. Smith ,  Peter Pushko ,  Michael Parker ,  George Ludwig

    IPC: A61K3912

    CPC classification number: C07K14/005 ,  A61K2039/5254 ,  C12N7/00 ,  C12N15/86 ,  C12N2770/36122 ,  C12N2770/36143 ,  C12N2770/36152 ,  C12N2770/36162 ,  C12N2840/20

    Abstract: The present invention provides a helper cell for expressing an infectious, replication defective, alphavirus particle in an alphavirus-permissive cell. The helper cell includes (a) a first helper RNA encoding (i) at least one alphavirus structural protein, and (ii) not encoding at least one alphavirus structural protein; and (b) a second helper RNA separate from the first helper RNA, the second helper RNA (i) not encoding the alphavirus structural protein encoded by the first helper RNA, and (ii) encoding the at least alphavirus one structural protein not encoded by the first helper RNA, such that all of the alphavirus structural proteins assemble together into alphavirus particles in the cell. Preferably, the helper cell also includes a replicon RNA encoding an alphavirus packaging sequence and an inserted heterogeneous RNA.

    Abstract translation: 本发明提供了用于在甲病毒允许细胞中表达感染性，复制缺陷型甲病毒颗粒的辅助细胞。 辅助细胞包括（a）编码（i）至少一种甲病毒结构蛋白的第一辅助RNA，和（ii）不编码至少一种甲病毒属结构蛋白; 和（b）与第一辅助RNA分开的第二辅助RNA，不编码由第一辅助RNA编码的甲病毒结构蛋白的第二辅助RNA（i），和（ii）编码至少一种不是由第一辅助RNA编码的结合蛋白的结构蛋白， 第一辅助RNA，使得所有甲病毒结构蛋白聚集在细胞中的甲病毒颗粒中。 优选地，辅助细胞还包括编码甲病毒包装序列和插入的异质RNA的复制子RNA。

    IDNA vaccines and methods for using the same
    26.
    发明授权
    IDNA vaccines and methods for using the same 失效
    IDNA疫苗及其使用方法

    公开(公告)号：US08691563B2

    公开(公告)日：2014-04-08

    申请号：US13054372

    申请日：2009-07-17

    Applicant: Peter Pushko ,  Igor Lukashevich

    Inventor： Peter Pushko ,  Igor Lukashevich

    IPC: C12N15/00 ,  C07H21/02 ,  A61K39/12

    CPC classification number: A61K39/193 ,  A61K39/12 ,  A61K2039/53 ,  C12N7/00 ,  C12N15/85 ,  C12N2770/24134 ,  C12N2770/24161 ,  C12N2770/36134 ,  C12N2770/36161 ,  Y02A50/388

    Abstract: Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.

    Abstract translation: 本文描述的是iDNA载体和疫苗及其使用方法。 iDNA在真核细胞中在体外或体内在致病性RNA病毒，特别是黄热病病毒和委内瑞兰马脑炎病毒中产生减毒疫苗。 当将iDNA注射到疫苗接受者中时，活体减毒病毒的RNA通过受体组织中的体内转录产生。 这引发疫苗接种者组织中后代减毒病毒的产生，以及引发保护免受野生型非减毒病毒的有效免疫应答。

    METHODS OF ENHANCING PROTEIN INCORPORATION INTO VIRUS LIKE PARTICLES
    29.
    发明申请
    METHODS OF ENHANCING PROTEIN INCORPORATION INTO VIRUS LIKE PARTICLES 审中-公开
    将蛋白质加入病毒颗粒的方法

    公开(公告)号：US20100143406A1

    公开(公告)日：2010-06-10

    申请号：US12306965

    申请日：2007-06-27

    Applicant: Gale SMITH ,  Peter Pushko

    Inventor： Gale SMITH ,  Peter Pushko

    IPC: A61K39/12 ,  C12N7/00

    CPC classification number: C07K14/005 ,  A61K2039/5258 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2710/14143 ,  C12N2740/16122 ,  C12N2760/16122 ,  C12N2810/6054

    Abstract: The present invention comprises a method of increasing glycoprotein incorporation on the surface of VLPs, comprising expressing a nucleic acid encoding a chimeric glycoprotein in a host cell, wherein said chimeric glycoprotein comprises the transmembrane domain of an influenza hemagglutinin protein. The invention also embodies specific VLPs comprising said chimeric glycoproteins and methods of inducing immunity in an animal utilizing said VLPs.

    Abstract translation: 本发明包括增加VLP表面上糖蛋白掺入的方法，包括在宿主细胞中表达编码嵌合糖蛋白的核酸，其中所述嵌合糖蛋白包含流感血凝素蛋白的跨膜结构域。 本发明还体现了包含所述嵌合糖蛋白的特异性VLP和利用所述VLP在动物中诱导免疫的方法。

Patent Agency Ranking